Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5178-5186

  Davies, E June ^a   Blackhall, Fiona H ^a   Shanks, Jonathan H ^b   David, Guido ^c   McGown, Alan T ^d   Swindell, Ric ^b   Slade, Richard J ^e   Martin Hirsch, Pierre ^f   Gallagher, John T ^a   Jayson, Gordon C ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e HOPE HOSPITAL   (United Kingdom)

^f ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN; PERLECAN; PROTEOHEPARAN SULFATE; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; SYNDECAN 4;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BIOPSY TECHNIQUE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CELL SURFACE; CLINICAL FEATURE; CONTROLLED STUDY; EPITHELIUM CELL; EVALUATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; OVARY ADENOCARCINOMA; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; EXTRACELLULAR MATRIX; FEMALE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; PROTEOGLYCANS; SYNDECAN-1; SYNDECAN-2; SYNDECAN-3; SYNDECAN-4; SYNDECANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 4143058069     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0103     Document Type: Article

References (44)

1. Blackhall FH, Merry CL, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer 2001;85:1094-8.
2. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001;12:89-98.
3. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Investig 1998;102:1599-608.
4. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Investig 2001;108:349-55.
5. Ostrovsky O, Berman B, Gallagher J, et al. Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem 2002;277:2444-53.
6. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65.
7. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994;269:11216-23.
8. Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, Gallagher JT. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J Biol Chem 1998;273:271-8.
9. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001;11:629-634.
10. Oh ES, Woods A, Lim ST, Theibert AW, Couchman JR. Syndecan-4 proteoglycan cytoplasmic domain and phosphatidyl 4,5-bisphosphate coordinately regulate protein kinase C activity. J Biol Chem 1998;273:10624-9.
11. Klass CM, Couchman JR, Woods A. Control of extracellular matrix assembly by syndecan-2 proteoglycan. J Cell Sci 2000;113:493-506.
12. Gonzalez AD, Kaya M, Shi W, et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line- specific manner. J Cell Biol 1998;141:1407-14.
13. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001;11:19R-23R.
14. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-10.
15. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signalling. Int J Cancer 2003;103:455-65.
16. Powell CA, Xu G, Filmus J, Busch S, Brody JS, Rothman PB. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest 2002;12:6S-7S.
17. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-12.
18. Kokenyesi R. Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. J Cell Biochem 2001;83:259-70.
19. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial [Erratum in: Lancet 2003;361:706]. Lancet 2002;360:505-15.
20. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial [Erratum in: Lancet 2003;361:706]. Lancet 2002;360:505-15.
21. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998;4:691-7.
22. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000;148:811-24.
23. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003;9:553-66.
24. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997;75:9-16.
25. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 1996;28:63-7.
26. Kumar-Singh S, Jacobs W, Dhaene K, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998;186:300-5.
27. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 1999;79:558-64.
28. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 1997;117:312-5.
29. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-I is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 2000;25:329-32.
30. Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999;112:377-83.
31. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer (Phila) 2003;98:474-83.
32. Wiksten JP, Lundin J, Nordling S, et al. Epitaelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 2001;95:1-6.
33. Parrott JA, Nilsson E, Mosher R, et al. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol 2001;175:29-39
34. Pupa SM, Menard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192:259-67.
35. Kleeff J, Wildi S, Kumbasar A, Friess H, Lander AD, Korc M. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas 1999;19:281-8.
36. Jaakkola P, Maatta A, Jalkanen M. The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner. Oncogene 1998;17:1279-86.
37. Jaakkola P, Jalkanen M. Transcriptional regulation of Syndecan-1 expression by growth factors. Prog Nucleic Acid Res Mol Biol 1999;63:109-38.
38. Obermair A, Speiser P, Reisenberger K, et al. Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett 1998;130:69-76.
39. Cannistra S. Cancer of the ovary. N Engl J Med 1993;329:1550-9.
40. Carey DJ, Conner K, Asundi VK, et al. cDNA cloning, genomic organization, and in vivo expression of rat N-syndecan. J Biol Chem 1997;272:2873-9.
41. Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-7.
42. Jayson GC, Vives C, Paraskeva C, et al. Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer 1999;82:298-304.
43. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 1998;273:51-7.
44. Molist A, Romaris M, Lindahl U, Villena J, Touab M, Bassols A. Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. Eur J Biochem 1998;254:371-7.